Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. - Wikidata - awgldk - TriplyDB

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

http://www.wikidata.org/entity/Q33406135

about

Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma : a meta-analysis of 37 trials Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives Novel agents for multiple myeloma to overcome resistance in phase III clinical trials Targeted treatments for multiple myeloma: specific role of carfilzomib A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma Trial Watch: Proteasomal inhibitors for anticancer therapy Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary re Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma Carfilzomib boosted combination therapy for relapsed multiple myeloma Association of response endpoints with survival outcomes in multiple myeloma.The emerging role of carfilzomib combination therapy in the management of multiple myeloma.New approaches to management of multiple myeloma.Carfilzomib in multiple myeloma.Novel agents and new therapeutic approaches for treatment of multiple myeloma.Current treatment landscape for relapsed and/or refractory multiple myeloma.An update on the use of lenalidomide for the treatment of multiple myeloma.Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making.Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma.Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.Emerging drugs and combinations to treat multiple myeloma.Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma.Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma.Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.Integration of Novel Agents into the Care of Patients with Multiple Myeloma.Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.

P2860

Q26741620-CFC3A356-DA08-471C-A9DC-72487C98DA4C Q26799104-78749F67-27A0-405A-AC8C-3E025CF8B17D Q26822754-208A3126-DEE9-4BE0-983F-590AABA62373 Q26996524-375EEA34-5AC3-4D9D-86CF-DE6121326242 Q28067148-F9C0871C-733B-4496-B296-5FF872F74BC9 Q28082910-B7E904DE-4871-4C22-8957-1485DEDF1387 Q30238893-4BD1C35B-B00A-45DA-998E-DF88177DC1F3 Q30802505-C8E04F1D-EF48-4430-929C-D653D42ED6BA Q33410213-499B2F6A-0525-4F47-9DEC-90E26C7DDF97 Q33412684-B8B955A5-FF08-4FFD-BBF1-E84A60E94C37 Q33423168-113129FE-CDF0-4C88-84CD-B2B64AA3C5BA Q33430690-DD0C41BD-94F1-403D-B761-44662B64ABED Q34788381-C216864C-C91A-44D7-A62F-9E81AA0E8135 Q35895152-0BDC68DF-37D5-4492-AB31-ABCAC9F74144 Q36020680-213A0787-B1AA-4142-ADBD-E08706A5789B Q36098363-288AA545-2DE3-4E6A-BAD2-62B5D6F22194 Q36274834-32DFAB0B-48AB-4B31-ACF8-1CB776CEAB1B Q36444233-A116A6E4-F802-47A0-8AFD-72F9B5C146EA Q36671445-D820BEA3-A146-4C7A-B76A-4DCCBEED2BAE Q37652953-B2F52C26-E124-4E2F-8019-4058564C6236 Q38122624-2A119C79-0F01-427E-95A7-DE85199C8D0C Q38187476-1E5FFA8F-D96A-4F02-95FC-5F9412C9F21D Q38191867-5A32463A-5F3D-4A58-9AA4-95B4D56DD201 Q38244558-6ACA9282-A6F3-4C94-989D-88620CC5A1EF Q38261677-650B81F4-F177-4776-B369-D69328754746 Q38271032-54F78092-7BEE-448E-BC70-8D865B96D970 Q38545607-044C1F8D-6AE7-4013-A79B-97001BE5DFAE Q38896473-1755EFBB-1520-479D-B31B-AA77EF02B91D Q38989789-BA1946BA-2A08-40DE-A661-6911423707DB Q39124257-910D6562-A73A-4FEF-A12A-824A4BF1D3F0 Q39138108-B7C2ECC7-7143-4A15-ACA9-F0573E78752D Q41531584-BD273587-1945-4386-8163-38437F2C8EC1 Q41694198-D0AB92CF-7CA5-4D9A-922D-046F7E8293BF Q42004227-38AEFB30-632C-4B25-A20D-8824E881AF95 Q42399854-CC60C963-DCF4-464E-85C8-5A9D180D850C Q42425704-2A5640B2-E7D5-4347-8513-C353C706A935 Q43921722-5913A596-201A-47E8-A8E6-D4981485C018 Q43994982-87BA0403-B944-4F5A-90E2-2F471B99809E Q46754093-3783E05F-3F81-4118-9526-827364E8ED01 Q47236245-EEC230E0-5EF3-427B-AD3A-97F489DFF78C

P2860

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

http://www.wikidata.org/entity/Q33406135

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Phase Ib dose-escalation study ...... progressive multiple myeloma.

@ast

Phase Ib dose-escalation study ...... progressive multiple myeloma.

@en

type

label

Phase Ib dose-escalation study ...... progressive multiple myeloma.

@ast

Phase Ib dose-escalation study ...... progressive multiple myeloma.

@en

prefLabel

Phase Ib dose-escalation study ...... progressive multiple myeloma.

@ast

Phase Ib dose-escalation study ...... progressive multiple myeloma.

@en

P1433

Q33406135-D99914E5-CEAB-4123-A287-FE06C68FBAC5

P1476

Q33406135-044964E7-975C-4F02-8479-5CA7A0E990CD

P2093

Q33406135-34DF62CA-6023-40BC-AA66-9120AA62A509

Q33406135-3A1C391B-72B0-47E8-94D3-A6F4156EEC12

Q33406135-4692A9D9-ED79-428D-8DA1-0BD64F0289A4

Q33406135-7D723BD5-690E-4C07-B7C7-5D4D4FC33AE6

Q33406135-A70EBDC8-6759-4770-8085-E50957C107D9

Q33406135-A8232DE6-EF42-484C-B593-443A0A9F80B5

Q33406135-BB3DFFF3-9508-4BA2-B84A-08A08E5245BE

Q33406135-CCAE4CE8-42DF-48F6-BBB9-F350DDF26A3A

P2860

Q33406135-00426692-FA1F-4020-9595-9E157F2FA74A

Q33406135-03445749-33A5-4EE7-AA23-2C6A3BC62E50

Q33406135-088AAA01-AA52-4EA4-A98B-F98776F8F545

Q33406135-0CEB007B-7B3A-4CCD-BADA-590C7A2CD862

Q33406135-212D9CC5-90E0-401C-9841-2BA4E797B56D

Q33406135-297FC437-AFAC-4A02-AED5-7BF8A06F0B7F

Q33406135-2BF95A83-BBAB-4616-9DE7-02E145B7A609

Q33406135-312B8316-B52C-4B5A-92B5-6F87C236D96E

Q33406135-37AC53FF-73DF-4531-A6DB-9A89140214A6

Q33406135-38D09B87-D574-4B8E-8D1A-4CDF2A3D442E

P304

Q33406135-8B3448BC-E9B6-4D86-B854-FC76E29EDD61

P31

Q33406135-5389889B-51D6-43D8-8FDC-854EC018CA9F

P356

Q33406135-7270A632-60E7-4C9C-9B5F-52BC25F4DDD3

P407

Q33406135-A27EA9B9-8050-4173-8C4B-3F6CE70EC0BF

P433

Q33406135-5167BDF5-AF8B-4447-955E-679660EFFB33

P478

Q33406135-B3C2CD7E-10A1-4AEB-A69E-F53A31514EF5

P50

Q33406135-91F35065-3ACB-4309-AD3E-B9A5CA2748E2

Q33406135-99B3AEC5-C235-41EF-BD26-7D87A94F6FE0

P577

Q33406135-36B4EA52-D05E-40D1-AC50-E68BFB5A045F

P698

Q33406135-6DCA4E87-9313-4917-A37D-342AA45A3D5C

P921

Q33406135-33EE005F-9A02-4F69-A0C5-FB5D2C74EB95

P932

Q33406135-1C8935D1-EC14-41BD-AD6D-EDDD768B3EB1

P356

1078-0432.CCR-12-3352

P1433

Clinical Cancer Research

P1476

Phase Ib dose-escalation study ...... progressive multiple myeloma.

@en

P2093

Alvin F Wong

http://www.w3.org/2001/XMLSchema#string

David S Siegel

http://www.w3.org/2001/XMLSchema#string

Lori A Kunkel

http://www.w3.org/2001/XMLSchema#string

Melissa Alsina

http://www.w3.org/2001/XMLSchema#string

Michael Wang

http://www.w3.org/2001/XMLSchema#string

Susan Lee

http://www.w3.org/2001/XMLSchema#string

Thomas G Martin

http://www.w3.org/2001/XMLSchema#string

William I Bensinger

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

P304

2248-2256

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-3352

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Robert Z Orlowski

Ruben Niesvizky

P577

2013-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23447001

http://www.w3.org/2001/XMLSchema#string

P921

P932

4149337

http://www.w3.org/2001/XMLSchema#string